Call for CTA@ Boston Applications Winter/Spring 2017 Program Placement - Deadline: October 13, 2016
Are you a Canadian IT, life sciences, robotics or foodtech company ready to grow and commercialize in the US market?
The Canadian Technology Accelerator in Boston is an award-winning 4-month immersion program that connects Canadian companies to US clients, strategic partners, and investors! Managed and operated by the Consulate General of Canada in Boston's Trade Commissioner Service team in close partnership with the CENE.
The Canadian Technology Accelerator in San Francisco - Life Sciences
The Canadian Technology Accelerator (CTA) program of Global Affairs Canada provides Canadian high-growth companies with mentoring support, networking opportunities and temporary office space for greater exposure to global partners and markets.
KalGene gears up to manufacture and test promising Alzheimer’s treatment with NRC, McGill and CIMTEC
October 3, 2016 – Montreal, QC, Toronto and Ottawa, ON ─ KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co-developing since 2015.
The treatment, a biologic molecule made up of a peptide that fights Alzheimer’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom-engineered therapeutic developed at NRC.
Pre-CAAP Company: TranQool Launches their 28 Day TranQool Challenge
Get Better with TranQool
OBIO Pre-CAAP company TranQool has recently launched their 28 Day TranQool Challenge, to become a happier you! This coincides with their visits to Ryerson University, George Brown College, and OCAD University to bring awareness about mental health to the campus and greater community while supporting the #popthestigma campaign.
CAAP Company: Brainfx’s New Medical App for Frontline Physicians And Clinicians - Address Critical Problem For ‘Undetected’ Brain Health Affecting Over 50 Million People
Sept 21, 2016 BrainFx Inc., a digital healthcare company, provides a software platform that helps assess the functional health of your brain, focusing on the milder brain dysfunction, while addressing the critical problem of misdiagnosis or delayed diagnosis of mild-to-moderate brain disorders and traumatic brain injuries (TBI) affecting over 50 million people in North America with an economic cost of over $100 billion.1
The company announced today the launch of BrainFx SCREENtm, a 15 minute point-of-care, mobile app for reliable initial pre-screening and early detection of possible mild to moderate brain dysfunctions and TBI’s; developed for frontline physicians and clinicians in the clinic, home or emergency room to deliver timely evaluation.
CAAP Company: Shift Health Finalist for Health 2.0's Global Retrospective Awards
Over the past nine years Health 2.0 has showcased and connected with thousands of technologies, companies, innovative thought leaders, and patient activists through our many events and conferences, challenges, code-a-thons, and more.
OBIO® CAAP Company Shift Health was selected as a finalist!
Visit the Health 2.0 site here, and cast a vote for Shift Health here!
Synaptive Medical Completes First Installation of Revolutionary Brain Surgery Technology at Mount Sinai Health System in New York
September 20, 2016, New York — Synaptive Medical, a medical device company relentlessly pursuing connections to transform the process of care, has successfully installed their BrightMatter™ technology at Mount Sinai Health System in New York City. Mount Sinai, ranked #12 in the country by U.S. News & World Report for its neurology and neurosurgery program, is the first hospital in the New York Metropolitan area to acquire this revolutionary technology.
For the full press release, click here
CAAP Company: Tecla Featured in a BELL Paralympics TV Commercial
Former OBIO CAAP Company Tecla is in the news again! This time featured in a BELL
Paralympics TV Commercial.
This commercial highlights the integration of everyday tech and assistive devices, we love the private cat too!
View the commercial here
OBIO CEO Gail Garland Provides Opening Remarks at MDCC's Strategic Entry into the U.S. MedTech Market Seminar
OBIO CEO Gail Garland was asked by MDCC to provide opening remarks at their hotly anticipated Strategic Entry into the U.S. MedTech Market for Canadian Firms Seminar.
The Greater MSP and MDCC brought to Toronto 4 world-class experts with backgrounds in finance, reimbursement, talent management and the FDA. Each shared their insights and tools for success for strategically entering into the U.S. MedTech market.
New Study Provides Further Evidence that Rna Disruption Assay™ (RDA™) May Be Useful Tool In Predicting Clinical Outcome Of Chemotherapy In Breast Cancer Patients
Further evidence RDA™ may predict clinical outcome of chemotherapy in Journal of the National Cancer Institute
A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients.
For the full press release, click here
For the Journal Article, click here
Pre-CAAP Company: SensOR Medical Featured at U OF T Engineering’s Entrepreneurship Hatchery Demo Day
Demo Day is the culmination of The Hatchery’s intensive summer program, where student teams work with experienced mentors — including executives, lawyers, medical professionals and engineers — to develop their business ideas and competencies. They receive detailed feedback and guidance on everything from patent applications and incorporation to honing their pitches and building prototypes, which they create using 3D printers and other fabrication resources provided by The Hatchery.
The seed funding at stake at Demo Day includes a grand prize of $20,000 and a runner-up prize of $10,000, donated by alumnus Anthony Lacavera (CompE 9T7), founder and chairman of Globalive Holdings and former CEO of WIND Mobile. An additional $2,500 Orozco prize is provided through funds raised by the students themselves.
For the full article, click here
CAAP Company: Tecla is helping those who live with Multiple Sclerosis
Former OBIO CAAP company Tecla is helping those who live with Multiple Sclerosis, learn about Michael's story today!
Medical Developments International Limited Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox® in Canada
Sept 11, 2016 Medical Developments International Limited ("MDI") (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox® (Low-Dose Methoxyflurane) Inhaler in Canada.
Penthrox® is a fast-acting, inhaled, non-narcotic analgesic drug/device combination for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.
For the full press release, click here
Self Care Catalysts: App to Support Self-Management for Primary Biliary Cholangitis (PBC)
September 09, 2016 - Toronto: To celebrate International PBC Day on September 11, 2016, Self Care Catalysts -- a patient intelligence and solutions company -- is announcing its newest self-care mobile app, created to support patients diagnosed with Primary Biliary Cholangitis (PBC). The team at Self Care Catalysts worked closely with the Canadian PBC Society to create a customized suite of self-care tools to support the total care for PBC, and to empower patients to play an active role in tracking their health story -- so that more can be understood about this rare disease.
For the full press release, click here
CAAP Company: Medella Health Wins James Dyson Award
The prize was awarded for their contact lens which could completely change how diabetics monitor their blood sugar.
The lens non-invasively monitors glucose levels and transmits the information to a mobile phone, Harry Gandhi, co-founder of Medella Health, told CBC News. Medella Health won the national prize in the James Dyson Award, a world-renowned design competition with a top national prize of $4,000.
For the full CBC article click here
For the CTV News feature, click here
Pre-CAAP Company: NERv Technologies selected as one of #Top500 Deeptech Startups!
Sept 6, 2016 NERv Technologies was selected as one of the top 500 Deep Tech startups at the upcoming Hello Tomorrow Global Summit in Paris.
Follow their journey on twitter here
OBIO's Very Own - Inspiring the Future at Rotman
OBIO's Dr. Klaus Fiebig, CAAP Senior Director, Strategic Programs was asked to be a panelist on the Rotman School of Management - University of Toronto - Start-up & Entrepreneurs Panel.
Overall, there was a strong buzz in the room with many enthusiastic MBA students evaluating if entrepreneurship and the startup world would be the right fit in their very near future, we certainly hope so!
Pre-CAAP Company: An Interview with TranQool therapist Dawn
Dawn joined TranQool because she felt that people need a platform where they can access counselling and services right at their fingertips.
TranQool enables you to talk with a real therapist in the comfort of your own home. You sign up. are matched with a therapist, have one-on-one video calls and build on your progress with assignments.
For the interview click here
100 Brains + 50 Locations = The Brain Project
100 brains, 50 locations all for 1 important cause: Brain Health!
The art installations can be found across Toronto and highlight the importance of brain health with the aim to improve the quality of life for those with dementia and other neurological disorders.
The project is being delivered by the Baycrest Foundation who see the project as a"catalyst for discussion and awareness of brain health."
Learn more here
Find a Brain Installation here
OBIO is Golden Horseshoe Bound
OBIO was invited to McMaster University by Susan Searls Giroux, Assistant Vice-President of McMaster University for a day filled with science, bus and partnerships.
The day started with a tour of the Biointerfaces Institute with the impressive John Brennan, Director of the Biointerfaces Institute. The discussion during the tour focused on diagnostics, cell therapies and biointerfaces and what the current and future needs will be for companies.